fbpx Skip to main content

Member's Profile

Oncolytics Biotech (US) Inc.

Location
4660 La Jolla Village Dr Ste 850
San Diego,   California
92122-4609
United States
Sector
Biotech
Membership Info
Membership Type: Industry
Membership Since: 2017
Need to make an update to your Member Profile or have a question? Contact us here: [email protected]
About Oncolytics Biotech (US) Inc.
Biotech Company
Oncolytics is a biotechnology company developing REOLYSIN®, an immuno-oncology viral-agent, as a potential treatment for a variety of tumor types. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses to treat a variety of cancers. Oncolytics’ clinical development program emphasizes three pillars: chemotherapy combinations to trigger selective tumor lysis; immuno-therapy combinations to produce adaptive immune responses; and immune modulator (IMiD) combinations to facilitate innate immune responses.  Oncolytics is currently planning its first registration study in breast cancer, as well as studies in combination with checkpoint inhibitors and IMID/targeted therapies in solid and hematological malignancies.  For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.
Related News
No related news posted by this Member